Intrathecal administration of neutralizing antibody against Fas ligand suppresses the progression of experimental autoimmune encephalomyelitis.

Authors: Okuda, Y  Sakoda, S  Fujimura, H  Nagata, S  Yanagihara, T  Bernard, C C 
Citation: Okuda Y, etal., Biochem Biophys Res Commun. 2000 Aug 18;275(1):164-8.
Pubmed: (View Article at PubMed) PMID:10944459
DOI: Full-text: DOI:10.1006/bbrc.2000.3279

A therapy aimed at blocking the Fas/Fas ligand (FasL) system was investigated using a relapsing form of experimental autoimmune encephalomyelitis (EAE) in mice, an animal model of multiple sclerosis (MS). Intracisternal administration of neutralizing antibody against FasL during the progression phase of EAE significantly reduced the severity of the disease with milder inflammation and myelin breakdown in the central nervous system (CNS). These results raised the possibility that the Fas/FasL system might contribute to tissue destruction in the CNS in the acute phase of EAE and that the intrathecal administration of neutralizing antibody against FasL may be beneficial for suppression of the acute phase of MS.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 12903984
Created: 2017-05-12
Species: All species
Last Modified: 2017-05-12
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.